Innoviva, Inc. (INVA) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $22.61, but acceptable to hold if already in. Reason: Earnings expected to decline ~65% (cyclical peak).
Innoviva earns royalties from GSK on RELVAR/BREO ELLIPTA and ANORO ELLIPTA at tiered rates, and markets five hospital-focused antibiotic and critical care products through its Innoviva Specialty Therapeutics unit. GSK royalties provide the majority of current revenues, with the... Read more
Hold if already holding. Not a fresh buy at $22.61, but acceptable to hold if already in. Reason: Earnings expected to decline ~65% (cyclical peak). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.4/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About Innoviva, Inc.
About Innoviva, Inc.
Innoviva's royalty portfolio earned revenue from two GSK-commercialized respiratory products — RELVAR/BREO ELLIPTA, under a tiered royalty of 15% on the first $3.0 billion in annual global net sales and 5% above, and ANORO ELLIPTA at 6.5-10% — which represent the majority of near-term revenues. The Innoviva Specialty Therapeutics platform expanded to five commercial products with NUZOLVENCE (zoliflodacin) receiving FDA approval in December 2025 for uncomplicated urogenital gonorrhea.
Royalty revenue is a function of GSK's global net sales of BREO and ANORO, both inhaled combination therapies for COPD and asthma marketed in the U.S., Canada, Japan, and Europe; Innoviva has no control over GSK's marketing strategy, pricing decisions, or formulary negotiations under the LABA Collaboration Agreement. The IST direct commercial products — GIAPREZA for septic shock, XACDURO for hospital-acquired pneumonia caused by Acinetobacter (FDA-approved May 2023, also approved in China May 2024), XERAVA for complicated intra-abdominal infections, ZEVTERA commercially launched in the U.S. in Q3 2025 under a license from Basilea Pharmaceutica Ltd, and NUZOLVENCE — are sold through Innoviva's own hospital-focused sales force. In Europe and Great Britain, GIAPREZA and XERAVA are distributed by PAION Deutschland GmbH (Humanwell Healthcare Group subsidiary), and XERAVA carries approvals across mainland China, Hong Kong, and other Asian markets licensed to Everest Medicines Limited.
Show full overview
Under the Inflation Reduction Act's drug price negotiation program, the Centers for Medicare & Medicaid Services will apply a negotiated maximum fair price to RELVAR/BREO ELLIPTA beginning January 1, 2027, and ANORO ELLIPTA has been selected for a subsequent negotiation cycle with its price expected to apply in 2028. The 10-K notes these government-negotiated prices may influence commercial market pricing through reference pricing and formulary positioning, which could reduce realized royalty rates beyond the direct Medicare channel impact.
See also: Healthcare · Biotechnology
From Innoviva, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-06-17Recent Developments — Innoviva, Inc.
Latest news
- NEWS Innoviva (INVA) to Release Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS Analysts Offer Insights on Healthcare Companies: Spectral AI (MDAI), NeOnc Technologies Holdings, Inc. (NTHI) and Innovi — The Globe and Mail neutral
- NEWS Cantor Fitzgerald reiterates Innoviva stock rating on royalty strength By Investing.com - Investing.com Australia — Investing.com Australia positive
- NEWS Cantor Fitzgerald reiterates Innoviva stock rating on royalty strength - Investing.com — Investing.com positive
- NEWS [Form 4] Innoviva, Inc. Insider Trading Activity - Stock Titan — Stock Titan neutral
Generated 2026-06-17T09:12:24Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerGSK10-K Item 1A: 'Currently, we derive the majority of our revenues from GSK and our near-term success depends in large part on GSK'
- MEDIUMProductRELVAR/BREO ELLIPTA and ANORO ELLIPTA10-K Item 1A: 'Royalty revenues from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® are expected to represent the majority of our foreseeable future revenues from GSK'
Material Events(8-K, last 90d)
- 2026-05-18Item 5.02LOWDirectors Derek Small and Mark DiPaolo resigned May 12, 2026 to focus on Syndeio BioSciences Inc. No disagreement with Company cited. Josephine Linden (former Goldman Sachs partner/MD) elected to Board effective May 18, 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $22.61, but acceptable to hold if already in. Reason: Earnings expected to decline ~65% (cyclical peak). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $30.18 (+33.5%), stop $21.41 (−5.6%), A.R:R 5.5:1. Score 6.4/10, moderate confidence.
Take-profit target: $30.18 (+33.5% upside). Target $30.18 (+33.5%), stop $21.41 (−5.6%), A.R:R 5.5:1. Stop-loss: $21.41.
Earnings expected to decline ~65% (cyclical peak).
Innoviva, Inc. trades at a P/E of 3.6 (forward 10.1). TrendMatrix value score: 9.0/10. Verdict: Hold.
11 analysts cover INVA with a consensus score of 4.1/5. Average price target: $36.
What does Innoviva, Inc. do?Innoviva earns royalties from GSK on RELVAR/BREO ELLIPTA and ANORO ELLIPTA at tiered rates, and markets five...
Innoviva earns royalties from GSK on RELVAR/BREO ELLIPTA and ANORO ELLIPTA at tiered rates, and markets five hospital-focused antibiotic and critical care products through its Innoviva Specialty Therapeutics unit. GSK royalties provide the majority of current revenues, with the royalty rate on BREO being 15% on annual net sales up to $3 billion and 5% above that.